| Data |
Ora |
Fonte |
Titolo |
|---|
| 20/12/2024 | 23:04 | EDGAR2 | Form S-3 - Registration statement under Securities Act of.. |
| 20/12/2024 | 22:15 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
| 18/12/2024 | 13:55 | GLOBE | ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend.. |
| 20/11/2024 | 13:55 | GLOBE | ZyVersa Therapeutics Announces Peer-Reviewed Publication.. |
| 15/11/2024 | 14:35 | GLOBE | Life Sciences Investor Forum: Presentations Now Available.. |
| 14/11/2024 | 14:30 | EDGAR2 | Form 8-K - Current report |
| 14/11/2024 | 14:10 | GLOBE | ZyVersa Therapeutics Reports Third Quarter, 2024 Financial.. |
| 14/11/2024 | 14:00 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 06/11/2024 | 14:00 | EDGAR2 | Form 8-K - Current report |
| 05/11/2024 | 13:00 | GLOBE | ZyVersa Therapeutics Highlights Published Data Demonstrating.. |
| 30/10/2024 | 21:30 | EDGAR2 | Form 8-K - Current report |
| 29/10/2024 | 12:57 | GLOBE | ZyVersa Therapeutics Highlights Review Article Supporting.. |
| 22/10/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Published Data Demonstrating.. |
| 17/10/2024 | 13:50 | GLOBE | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter.. |
| 15/10/2024 | 13:50 | GLOBE | ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured.. |
| 07/10/2024 | 13:55 | GLOBE | ZyVersa Therapeutics Forms New Scientific Advisory Board to.. |
| 16/9/2024 | 23:30 | EDGAR2 | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 16/9/2024 | 23:29 | EDGAR2 | Form 8-K - Current report |
| 10/9/2024 | 13:25 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 10/9/2024 | 13:22 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 10/9/2024 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
| 09/9/2024 | 22:32 | EDGAR2 | Form DEFA14A - Additional definitive proxy soliciting.. |
| 09/9/2024 | 22:30 | EDGAR2 | Form DEF 14A - Other definitive proxy statements |
| 03/9/2024 | 23:29 | EDGAR2 | Form S-3 - Registration statement under Securities Act of.. |
| 03/9/2024 | 23:28 | EDGAR2 | Form S-3 - Registration statement under Securities Act of.. |
| 30/8/2024 | 23:10 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
| 09/8/2024 | 22:40 | GLOBE | ZyVersa Therapeutics Reports Second Quarter, 2024 Financial.. |
| 09/8/2024 | 22:30 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 07/8/2024 | 13:50 | GLOBE | ZyVersa Therapeutics Announces Published Data Supporting the.. |
| 01/8/2024 | 14:00 | EDGAR2 | Form 8-K - Current report |
| 29/7/2024 | 13:45 | GLOBE | ZyVersa Therapeutics Announces Published Data Demonstrating.. |
| 25/7/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Selects Obesity and Related Metabolic.. |
| 19/7/2024 | 03:35 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 19/7/2024 | 03:35 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 19/7/2024 | 03:35 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 18/7/2024 | 17:18 | GLOBE | ZyVersa Therapeutics Announces Publication Demonstrating.. |
| 09/7/2024 | 13:57 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited.. |
| 15/5/2024 | 14:35 | GLOBE | ZyVersa Therapeutics Reports First Quarter, 2024 Financial.. |
| 15/5/2024 | 14:30 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 15/5/2024 | 14:25 | EDGAR2 | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K.. |
| 14/5/2024 | 13:57 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate.. |
| 29/4/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Announces Publication Reinforcing the.. |
| 04/4/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Published Data Demonstrating.. |
| 25/3/2024 | 13:17 | GLOBE | ZyVersa Therapeutics Reports Full Year 2023 Financial.. |
| 18/3/2024 | 12:57 | GLOBE | ZyVersa Therapeutics Announces IRB Approval of Phase 2a.. |
| 14/3/2024 | 12:57 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate.. |
| 08/3/2024 | 23:00 | EDGAR2 | Form 8-K - Current report |
| 08/3/2024 | 23:00 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
| 29/2/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Generated Approximately $2.7 Million.. |
| 28/2/2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Data from Review Article.. |
Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
